Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06692764 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure
A Phase 2 study of Atherosclerotic Cardiovascular Disease, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 202
- Enrollment target
- 20
- Study locations
NCT06692764: Completed Phase 2 study of Atherosclerotic Cardiovascular Disease, sponsored by AstraZeneca.
NCT06692764 is a Phase 2 study of Atherosclerotic Cardiovascular Disease that has completed, run by AstraZeneca. The registered enrollment target is 202 participants, below the 7,558-participant average among 21 other Atherosclerotic Cardiovascular Disease trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06692764, a Phase 2 study of Atherosclerotic Cardiovascular Disease, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 202 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase II, multi-centre, randomized, double-blind, placebo-controlled, crossover study to evaluate the effect of AZD0780 Dose 1 versus placebo on systolic blood pressure (SBP) at Week 4, as measured by 24-hour ambulatory blood pressure monitoring (ABPM) in participants with ASCVD or risk equivalents and LDL-C ≥ 70 mg/dL, on stable medication.
Primary Outcome
Change from baseline in ambulatory 24-hour average systolic blood pressure (SBP) at Week 4
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AZD0780
Study Locations (20)
Florida
- Research Site - Boca Raton
- Research Site - Hialeah
- Research Site - Jacksonville
- Research Site - Miami
- Research Site - Miami
- Research Site - Miami
- Research Site - Miami
- Research Site - Ocala
- Research Site - Port Orange
- Research Site - Tamarac
California
- Research Site - Inglewood
- Research Site - Northridge
- Research Site - Pomona
Illinois
- Research Site - Chicago
Maryland
- Research Site - Potomac
Massachusetts
- Research Site - New Bedford
New York
- Research Site - New Windsor
Ohio
- Research Site - Beavercreek
Pennsylvania
- Research Site - Horsham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 202 participants |
| Start Date | 2024-10-30 |
| Est. Completion | 2025-05-02 |
| Phase | Phase 2 |
What the finished NCT06692764 record still lists
NCT06692764 is an interventional study that assigns participants to a tested intervention. The registered 202 participants enrollment target is mid-sized for trials with a published cap, below the 7,558-participant average among 21 other Atherosclerotic Cardiovascular Disease trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Atherosclerotic Cardiovascular Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06692764 names 20 study sites across 9 states, led by Florida, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT06692764 about?
NCT06692764 is a clinical study titled "A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure". This is a Phase II, multi-centre, randomized, double-blind, placebo-controlled, crossover study to evaluate the effect of AZD0780 Dose 1 versus placebo on systolic blood pressure (SBP) at Week 4, as measured by 24-hour ambulatory blood pressure monitoring (ABPM) in participants with ASCVD or risk eq...
What is the current status of trial NCT06692764?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 202 participants. The study started on 2024-10-30. Estimated completion is 2025-05-02.
What conditions does trial NCT06692764 study?
This clinical trial studies the following conditions: Atherosclerotic Cardiovascular Disease.
What interventions are being tested in trial NCT06692764?
The interventions under investigation include: Placebo (DRUG), AZD0780 (DRUG).
Who is sponsoring clinical trial NCT06692764?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06692764 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atherosclerotic Cardiovascular Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06692764's enrollment target sits among peer trials
202 16th of 21 higher than 6 of 21 other Atherosclerotic Cardiovascular Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atherosclerotic Cardiovascular Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
RECRUITING · Phase 2
-
An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol
COMPLETED · Phase 2
-
A Pragmatic INitiative for LDL-C Management by a CLinical Pharmacist-Led Team Among Atherosclerotic CardiovascUlar DisEase Patients
RECRUITING · NA
-
The Prevent Coronary Artery Disease Trial
RECRUITING · Phase 3
-
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
RECRUITING · Phase 3
-
Polygenic Risk Score Implementation and Stratification for Managing Blood Pressure
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05272254 · 202 participants · Phase 2
Povidone Iodine Efficacy Study
- NCT05701280 · 202 participants · NA
Pilot/Pivotal Study of DBS+Rehab After Stroke
- NCT05932589 · 202 participants
Neurophysiologic Biomarkers in Rett Syndrome
- NCT06014931 · 202 participants · NA
Telehealth-enhanced Patient-oriented Recovery Trajectory After Intensive Care
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI